Patrick James Orme

Array ( [id] => 7275593 [patent_doc_number] => 20040235044 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2004-11-25 [patent_title] => 'Chain-shortened polynucleotide and method for preparation thereof' [patent_app_type] => new [patent_app_number] => 10/873797 [patent_app_country] => US [patent_app_date] => 2004-06-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8705 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0235/20040235044.pdf [firstpage_image] =>[orig_patent_app_number] => 10873797 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5924065 [patent_doc_number] => 20060241072 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2006-10-26 [patent_title] => 'Oligomeric compounds for use in gene modulation' [patent_app_type] => utility [patent_app_number] => 10/561618 [patent_app_country] => US [patent_app_date] => 2004-06-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 43483 [patent_no_of_claims] => 44 [patent_no_of_ind_claims] => 9 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0241/20060241072.pdf [firstpage_image] =>[orig_patent_app_number] => 10561618 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7434570 [patent_doc_number] => 20040266718 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2004-12-30 [patent_title] => 'Inhibition of specific histone deacetylase isoforms' [patent_app_type] => new [patent_app_number] => 10/870587 [patent_app_country] => US [patent_app_date] => 2004-06-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 38 [patent_figures_cnt] => 38 [patent_no_of_words] => 17277 [patent_no_of_claims] => 48 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0266/20040266718.pdf [firstpage_image] =>[orig_patent_app_number] => 10870587 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7966217 [patent_doc_number] => 07939503 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2011-05-10 [patent_title] => 'Reduction of cell-cell communication in prostate cancer using STEAP-1 siRNA' [patent_app_type] => utility [patent_app_number] => 10/861662 [patent_app_country] => US [patent_app_date] => 2004-06-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 81 [patent_figures_cnt] => 80 [patent_no_of_words] => 89970 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 56 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/07/939/07939503.pdf [firstpage_image] =>[orig_patent_app_number] => 10861662 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 32702 [patent_doc_number] => 07790691 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2010-09-07 [patent_title] => 'Double stranded compositions comprising a 3′-endo modified strand for use in gene modulation' [patent_app_type] => utility [patent_app_number] => 10/561324 [patent_app_country] => US [patent_app_date] => 2004-06-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 44280 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 126 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/07/790/07790691.pdf [firstpage_image] =>[orig_patent_app_number] => 10561324 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5349968 [patent_doc_number] => 20090005329 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2009-01-01 [patent_title] => 'NUCLEIC ACID BASED LADDER COPOLYMERS' [patent_app_type] => utility [patent_app_number] => 10/855893 [patent_app_country] => US [patent_app_date] => 2004-05-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 10983 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0005/20090005329.pdf [firstpage_image] =>[orig_patent_app_number] => 10855893 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5051896 [patent_doc_number] => 20070032441 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2007-02-08 [patent_title] => 'Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (sina)' [patent_app_type] => utility [patent_app_number] => 10/557542 [patent_app_country] => US [patent_app_date] => 2004-05-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 130 [patent_figures_cnt] => 130 [patent_no_of_words] => 123862 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0032/20070032441.pdf [firstpage_image] =>[orig_patent_app_number] => 10557542 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6971677 [patent_doc_number] => 20050037387 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2005-02-17 [patent_title] => 'Modulation of the RNA interference pathway' [patent_app_type] => utility [patent_app_number] => 10/852630 [patent_app_country] => US [patent_app_date] => 2004-05-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38059 [patent_no_of_claims] => 90 [patent_no_of_ind_claims] => 9 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0037/20050037387.pdf [firstpage_image] =>[orig_patent_app_number] => 10852630 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7190302 [patent_doc_number] => 20040204380 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2004-10-14 [patent_title] => 'Antisense modulation of novel anti-apoptotic bcl-2-related proteins' [patent_app_type] => new [patent_app_number] => 10/844470 [patent_app_country] => US [patent_app_date] => 2004-05-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18860 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 3 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0204/20040204380.pdf [firstpage_image] =>[orig_patent_app_number] => 10844470 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7447031 [patent_doc_number] => 20040186069 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2004-09-23 [patent_title] => 'Antisense modulation of tumor necrosis factor receptor 2 expression' [patent_app_type] => new [patent_app_number] => 10/476021 [patent_app_country] => US [patent_app_date] => 2004-05-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26864 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0186/20040186069.pdf [firstpage_image] =>[orig_patent_app_number] => 10476021 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6926431 [patent_doc_number] => 20050239687 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2005-10-27 [patent_title] => 'Methods and compositions for delivering siRNA into mammalian cells' [patent_app_type] => utility [patent_app_number] => 10/831342 [patent_app_country] => US [patent_app_date] => 2004-04-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 8124 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0239/20050239687.pdf [firstpage_image] =>[orig_patent_app_number] => 10831342 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7346752 [patent_doc_number] => 20040192632 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2004-09-30 [patent_title] => 'Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes' [patent_app_type] => new [patent_app_number] => 10/832941 [patent_app_country] => US [patent_app_date] => 2004-04-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 34 [patent_figures_cnt] => 34 [patent_no_of_words] => 32096 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0192/20040192632.pdf [firstpage_image] =>[orig_patent_app_number] => 10832941 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7020044 [patent_doc_number] => 20050222063 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2005-10-06 [patent_title] => 'Methylenetetrahydrofolate reductase inhibitors and use thereof' [patent_app_type] => utility [patent_app_number] => 10/831759 [patent_app_country] => US [patent_app_date] => 2004-04-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 25 [patent_no_of_words] => 20058 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0222/20050222063.pdf [firstpage_image] =>[orig_patent_app_number] => 10831759 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7181220 [patent_doc_number] => 20040202652 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2004-10-14 [patent_title] => 'Methods and compositions for control of bone formation via modulation of leptin activity' [patent_app_type] => new [patent_app_number] => 10/830922 [patent_app_country] => US [patent_app_date] => 2004-04-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 37 [patent_figures_cnt] => 37 [patent_no_of_words] => 36232 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0202/20040202652.pdf [firstpage_image] =>[orig_patent_app_number] => 10830922 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7318968 [patent_doc_number] => 20040224914 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2004-11-11 [patent_title] => 'Method for treatment of angiogenic disorders' [patent_app_type] => new [patent_app_number] => 10/828395 [patent_app_country] => US [patent_app_date] => 2004-04-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 4003 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0224/20040224914.pdf [firstpage_image] =>[orig_patent_app_number] => 10828395 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7377917 [patent_doc_number] => 20040220131 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2004-11-04 [patent_title] => 'Method for treatment of cancerous angiogenic disorders' [patent_app_type] => new [patent_app_number] => 10/828394 [patent_app_country] => US [patent_app_date] => 2004-04-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 3292 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0220/20040220131.pdf [firstpage_image] =>[orig_patent_app_number] => 10828394 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5178040 [patent_doc_number] => 20070179100 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2007-08-02 [patent_title] => 'Protected monomers' [patent_app_type] => utility [patent_app_number] => 10/553659 [patent_app_country] => US [patent_app_date] => 2004-04-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 106306 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0179/20070179100.pdf [firstpage_image] =>[orig_patent_app_number] => 10553659 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7353293 [patent_doc_number] => 20040249130 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2004-12-09 [patent_title] => 'Aptamer-toxin molecules and methods for using same' [patent_app_type] => new [patent_app_number] => 10/826077 [patent_app_country] => US [patent_app_date] => 2004-04-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 30449 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0249/20040249130.pdf [firstpage_image] =>[orig_patent_app_number] => 10826077 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7276285 [patent_doc_number] => 20040235736 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2004-11-25 [patent_title] => 'Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms' [patent_app_type] => new [patent_app_number] => 10/824058 [patent_app_country] => US [patent_app_date] => 2004-04-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 33576 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0235/20040235736.pdf [firstpage_image] =>[orig_patent_app_number] => 10824058 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 236323 [patent_doc_number] => 07595304 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2009-09-29 [patent_title] => 'Polymeric oligonucleotide prodrugs' [patent_app_type] => utility [patent_app_number] => 10/822205 [patent_app_country] => US [patent_app_date] => 2004-04-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 13 [patent_no_of_words] => 12694 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 28 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/07/595/07595304.pdf [firstpage_image] =>[orig_patent_app_number] => 10822205 [rel_patent_id] =>[rel_patent_doc_number] =>)